High levels of two proteins in the blood, called KL-6 and CCL-18, may work as biomarkers for predicting disease severity and progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) patients, Phase 2 trial data suggest. The study, “Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease…
News
Older age, active digital ulcers, lung tissue scarring, muscle weakness, and increased levels of C-reactive protein (CRP) are predictive factors of progressive organ damage in people with systemic sclerosis (SSc), a study has found. Taking these factors into consideration may help clinicians to identify patients at risk of SSc worsening,…
Tagraxofusp, a medicine approved in the U.S. under the name Elzonris to treat a rare blood cancer, may help decrease levels of immune cells that promote inflammation in systemic sclerosis (SSc), new preclinical data suggest. The results were shared in a poster, “CD123+ plasmacytoid dendritic cells (pDCs) from…
A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…
Injections of hyaluronidase, marketed as Hylenex, among other names, improved the ability to eat and reduced difficulties in opening the mouth and dental care in a woman with scleroderma, according to a new case report. The case was described in a study, “Hyaluronidase Treatment of…
Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with a holistic,…
Treatment with pirfenidone fails to improve lung function in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD), results of a clinical trial show. Trial results were discussed at the 2019 Annual European Congress of Rheumatology (EULAR) in Madrid, during an oral presentation titled “…
People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So how does the…
Higher blood viscosity may help clinicians identify patients with systemic sclerosis at risk of having pulmonary arterial hypertension (PAH), a serious life-threatening respiratory complication. The finding was reported by Turkish researchers in the study “Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?”…
News
Lenabasum Promotes Sustained Improvements in Systemic Sclerosis Patients, Extension Study Shows
People with diffuse cutaneous systemic sclerosis (dcSSc) treated with lenabasum keep improving after 21 months of treatment, results from a Phase 2 open-label extension study show. Robert Spiera, MD, from Weill Cornell Medical College, New York, and principal investigator of the Phase 2 study, shared the data in…
Recent Posts
- Genetic links to systemic sclerosis may differ by sex, new study finds
- Autoantibodies tied to symptoms, complications in scleroderma study
- Liver enzyme levels help diagnose autoimmune hepatitis in SSc: Study
- Stem cell transplant safely eases scleroderma symptoms for teen
- New study flags existing medications as possible scleroderma treatments
- Anti-CD146 antibodies may signal occupational exposure in SSc: Study
- New SSc drug safely cuts Raynaud’s attack duration, eases symptoms
- Carbon dioxide hand baths may help in SSc-related Raynaud’s, study finds
- More SSc-ILD patients receive early treatment, new study finds
- CD13 levels elevated in scleroderma, but biomarker value unclear